All right, thanks for taking the questions. Okay, and then based on your expectations of enrolling 90 to 100 sites in the Phase III, assuming--letÂ's assume you start in the fourth quarter, when would you expect the interim analysis to hit, and the primary endpoint as well? Frank Bedu-Addo actual occurrence of these events. ItÂ's not very easy to predict exactly when that time will occur, but the initial interim endpoint will be right after the completed enrolment for the trial, so that could be anywhere be ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to _____________ Commission file number 001-37568 PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) Delaware 26-4 ...

PDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2023 Earnings Conference Call May 15, 2023 8:00 AM ET Operator It's now my pleasure to turn the call over to your host, Gabby DeGravina, Investor Relations. Please go ahead, Gabby. Good morning, and welcome to PDS Biotechnology's first quarter 2023 earnings conference call and audio webcast. Before we begin, we need to remind everyone that on today's call, the company will be making forward-looking statements regarding regulatory and clinical candidate developm ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ( Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to ________ Commission file number 001-37568 PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) Delaware 26-4231384 (State or other jur ...

Frank Bedu-Addo I can't really comment regarding Infectimune presentations. The Viruses publications were very, very impressive for us in terms of the ability to demonstrate broad antigen specific CD4s and CD8 cells that are indeed protected from lethal influenza challenge. And I think any scientific presentations during the rest of this year will be guided by additional preclinical studies that we may be pursuing with the goal of progressing our Infectimune based platform to human clinical trials. We think ...

CFA + TARP (1-20) X Versamune® + TARP (1-20) 1 Reference: Wood LV et al, Oncoimmunology, 2016, Vol. 5 (8) CFA –Complete Freund's Adjuvant a highly potent immune activator not used in humans due to potentially lethal toxicity *Reference: Surveillance Research Program, National Cancer Institute SEER Assumes $150K for annual course of therapy; in line with current immunotherapy treatment.Assessments have not been adjusted to reflect TARP expression, which is currently unknown by tumor type 243 PDS0103: MUC1 An ...

PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2022 Results Conference Call November 14, 2022 8:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Matt Hill - Chief Financial Officer Conference Call Participants Carvey Leung - Cantor Fitzgerald Laura Suriel - Alliance Global Partners Robert LeBoyer - Noble Capital Operator Greetings. Welcome to PDS Biotech's Third Quarter 2022 Earnings Conference Ca ...

PDS Biotechnology Corporation (NASDAQ:PDSB) Q2 2022 Results Earnings Conference Call August 8, 2022 8:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Matthew Hill - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Fitzgerald James Molloy - Alliance Global Partners Leland Gershell - Oppenheimer & Co. Joseph Pantginis - H. C. Wainwright & Co. Robert LeBoyer - Noble Capital ...

INVESTOR PRESENTATION NASDAQ: PDSB| June 2022 S PDS Biotechnology Precision Designed Science For Immunotherapy Forward-Looking Statements Certain information in this presentation may include forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the "Company") and other matters. These statements may discuss goals ...

PDS Biotechnology Corporation. (NASDAQ:PDSB) Q1 2022 Earnings Conference Call May 11, 2022 8:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Matthew Hill - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Leland Gershell - Oppenheimer Laura Suriel - Alliance Global Partners Robert LeBoyer - Noble Capital Operator Hello and welcome to PDS Biotechnology First Qua ...